GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Indinavir

Historical U.S. label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

CRIXIVAN (indinavir sulfate) capsules

Product / population
Historical adult oral HIV product. Not an assertion of current U.S. marketing.
Renal measure
Not specified; verify before use

Selected product data list a marketing end date of October 24, 2021. This is an archived label, not a new-drug addition.

Historical labeled adult dose

The labeled adult regimen is 800 mg orally every 8 hours. Take with water, at least 1 hour before or 2 hours after a meal; a light meal is an alternative. Combination therapy and interacting medicines require separate review.

Renal evidence and limitations

The label reports no renal-impairment pharmacokinetic study and supplies no numeric renal-adjustment table. Removal by hemodialysis or peritoneal dialysis is unknown. Nephrolithiasis or urolithiasis may require temporary interruption for 1-3 days or discontinuation, with clinical management of hydration.

Source revision: 05/2018 | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f

Scope: Historical exact U.S. label imported to fill the empty original source page; current availability is not established. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition

Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: See source.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Preserved GlobalRPh source

Original GlobalRPh protocol and comments

Preserved source. Not revalidated as current labeling.

Method: Use the measure stated in the original section.

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeCRIXIVAN (indinavir sulfate) capsulesRenal Drug Handbook, fifth edition
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Source-content exception: the live original page is empty apart from its heading. This does not establish a no-adjustment recommendation.

The separate CRIXIVAN label summary supplies actual historical dosing. It is not presented as missing text recovered from the original GlobalRPh page.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/indinavir/

Original GlobalRPh page status

The GlobalRPh renal directory contains an Indinavir entry. The retrieved individual page contains the Indinavir heading but no usual-dose, renal-dose or dialysis text. No missing GlobalRPh recommendation has been invented. This source-specific page is retained so the directory entry is not lost; separately attributed official-label material is required to populate clinical dosing.

GRPH-indinavir-01 · Source section: Original GlobalRPh page statusRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

CRIXIVAN (indinavir sulfate) capsules

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Historical adult oral HIV product. Not an assertion of current U.S. marketing.

Renal method: Not specified in this summary.
Source date: 05/2018
Retrieved: 2026-09-05

Historical exact U.S. label imported to fill the empty original source page; current availability is not established.

Historical labeled adult dose

The labeled adult regimen is 800 mg orally every 8 hours. Take with water, at least 1 hour before or 2 hours after a meal; a light meal is an alternative. Combination therapy and interacting medicines require separate review.

indinavir:dm-e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f-1 · Source locator: DOSAGE AND ADMINISTRATION; PDF page 25

Renal evidence and limitations

The label reports no renal-impairment pharmacokinetic study and supplies no numeric renal-adjustment table. Removal by hemodialysis or peritoneal dialysis is unknown. Nephrolithiasis or urolithiasis may require temporary interruption for 1-3 days or discontinuation, with clinical management of hydration.

indinavir:dm-e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f-2 · Source locator: CLINICAL PHARMACOLOGY; WARNINGS; OVERDOSAGE; DOSAGE AND ADMINISTRATION

Source-specific limits

Selected product data list a marketing end date of October 24, 2021. This is an archived label, not a new-drug addition.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f
Retrieved
2026-09-05
Exact label title
CRIXIVAN (indinavir sulfate) capsules
DailyMed Set ID
e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f
Labeler
Merck Sharp & Dohme LLC
DailyMed page updated
2023-01 (SPL product-data revision)
Label revision
05/2018
FDA application
NDA020685
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
877cc416631e365cd6821dc4def4d3df7aabed6b1986bc0eee8e6d2925877522
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition

Open / share this exact local source

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Historical renal guidance

The 20-50, 10-20 and <10 mL/min bands retain normal dosing with close monitoring. APD/CAPD, HD and high-flux HDF refer to <10; CAV/VVHD refers to 10-20. The book describes removal as unlikely with APD/CAPD and CAV/VVHD and absent with HD/high-flux HDF.

indinavir:rdh5-521-522-1 · Source locator: Printed page 521: renal impairment and renal replacement

Stone-related caution

The handbook discusses crystalluria and nephrolithiasis, including temporary interruption for 1-3 days when flank pain occurs, with or without hematuria.

indinavir:rdh5-521-522-2 · Source locator: Printed page 522: Other information

Source-specific limits

The archived U.S. label states that HD/PD removal is unknown, whereas the book uses more definite dialyzability categories. Preserve this disagreement. This entry is retained from the mandatory GlobalRPh baseline and is not classified as a currently marketed new U.S. drug.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 521-522; PDF page 540-541
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
eb8f5d8b190957cd715cde0e4c333d8ef37cf79dd929e04a73ae94caa0e5202b

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/indinavir/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
126440b29fbd294b6c812ee6e00e68781861aed1d57a962f699813ebc7cae5cb
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report